ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

DeVita Suggest “Overlay Consortium” as Outreach Mechanism for Southern California, Other Areas

September 28, 1984

Varmus’s 2016 Bypass Budget Seeks “Modest” Increase of $823 Million

December 5, 2014

Authorization Bill Passes Senate 82-0

June 27, 1980

NCCN, McKesson Form Partnership To Build Clinical Support Software

November 30, 2012

Program Announcements, RFA In Radiation Effects Available

September 24, 1982

NSAIDs Cut Oral Cancer Risk But Raise Smokers’ Heart Risk

October 28, 2005